5-甲基-5-吡啶-4-基-咪唑烷-2,4-二酮 | 6294-54-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 5-甲基-5-吡啶-4-基-咪唑烷-2,4-二酮
• 英文名称: 5-methyl-5-(pyridin-4-yl)imidazolidine-2,4-dione
• 英文别名: 5-methyl-5-(4-pyridyl)-2,4-imidazolidene dione；5-methyl-5-(4-pyridyl)-2,4-imidazolidenedione；5-methyl-5-(4-pyridyl)-2,4-imidazolidinedione；5-methyl-5-[4]pyridyl-imidazolidine-2,4-dione；5-methyl-5-(4-pyridyl)hydantoin；5-methyl-5(4-pyridyl)hydantoin；5-methyl-5-pyridin-4-ylimidazolidine-2,4-dione
• CAS: 6294-54-8
• 化学式: C₉H₉N₃O₂
• mdl: MFCD01828926
• 分子量: 191.189
• InChiKey: OWAMLUWBGKKQEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  71.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  potassium tetrachloropalladate(II) 、 5-甲基-5-吡啶-4-基-咪唑烷-2,4-二酮 以 乙醇 、 水 为溶剂， 反应 6.0h， 以89%的产率得到trans-dichlorobis(5-methyl-5-(4-pyridyl)hydantoin)palladium(II)
  参考文献：
  名称：

  Pd(II) and Pd(IV) complexes with 5-methyl-5-(4-pyridyl)hydantoin: Synthesis, physicochemical, theoretical, and pharmacological investigation

  摘要：

  The reaction of K-2[PdCl4] and PdCl2 with 5-methyl-5-(4-pyridy1)-2,4-imidazolidenedione (L) proceeded with the formation of two different Pd complexes, PdL2Cl2 (1) and PdL2Cl4 (2c), corresponded to a substitution reaction and a substitution reaction along with unanticipated oxidation, respectively. The nature of the oxidizing agent is unknown. These compounds have been studied by elemental analysis, IR, H-1 and (CNMR)-C-13, molar conductivity, and cyclic voltammetry. In addition, structural optimization by DFT calculations and simulation of NMR spectra have been performed and compared with the experimental data. NBO analysis, HOMO and LUMO, have been used to elucidate the information regarding charge transfer within the molecules. Theoretical studies confirmed that in 1 and 2c the trans structures are about 41 and 33 kJ mol(-1) more stable than cis ones. Antibacterial activity and in vitro cytotoxicity of these compounds, as respectively assessed in six bacterial strains and two human tumor cell lines, have been investigated. Results showed the title complexes have the capacity of inhibiting the metabolic growth of bacteria and tumor cells to different extents. (C) 2014 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.saa.2014.08.002
• 作为产物：
  描述：

  4-乙酰吡啶 在 ammonium carbonate 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 生成 5-甲基-5-吡啶-4-基-咪唑烷-2,4-二酮
  参考文献：
  名称：

  2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them

  摘要：

  本发明涉及式I的咪唑啉化合物，式I的化合物是有价值的药用活性化合物，例如，适用于治疗和预防炎症性疾病，例如类风湿关节炎，或过敏性疾病。式I的化合物是白细胞粘附和迁移的抑制剂和/或整合素群中属于粘附受体VLA-4的拮抗剂。它们通常适用于治疗或预防由白细胞粘附和/或白细胞迁移的不良程度引起的疾病，或与之相关的疾病，或者在其中基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用发挥作用。本发明还涉及制备式I化合物的方法，它们在治疗和预防上述疾病状态的使用以及含有式I化合物的制药制剂。

  公开号：

  US06423712B1

文献信息

• [EN] THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS<br/>[FR] COMPOSES THERAPEUTIQUES DESTINES AU TRAITEMENT D'ETATS DYSLIPIDEMIQUES
  申请人：MERCK & CO INC

  公开号：WO2004011448A1

  公开（公告）日：2004-02-05

  The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

  本发明涉及式I的新LXR配体及其药用可接受的盐、酯和互变异构体，它们在治疗血脂异常状况，特别是低HDL胆固醇水平方面具有用途。
• CARBINOL DERIVATIVES HAVING CYCLIC LINKER
  申请人：Yamaguchi Yuki

  公开号：US20100048610A1

  公开（公告）日：2010-02-25

  [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎性细胞因子引起的炎症性疾病；过敏性皮肤病；糖尿病；或阿尔茨海默病的治疗剂。【解决手段】以下一般式（I）所表示的羟甲基化合物或其盐，或其溶剂化合物。
• New Rh(III) complexes of 5-methyl-5-(pyridyl)-2,4-imidazolidenedione: Synthesis, X-ray structure, electrochemical study and catalytic behaviour for hydrogenation of ketones
  作者：Seyyed Javad Sabounchei、Mohsen Sayadi、Mojdeh Sadat Hashemi、Ali Hashemi、Davood Nematollahi、Eslam Salahifar、Robert W. Gable

  DOI：10.1002/aoc.3716

  日期：2017.10

  We describe the reaction of anion [RhCl6]3− with a series of hydantoin ligands (HL1, HL2 and HL3 = 5‐methyl‐5‐(2‐, 3‐ and 4‐pyridyl)‐2,4‐imidazolidenedione, respectively). Based on spectroscopic, cyclic voltammetric, elemental and MS analyses, the complexes have the general formula K[RhCl2(L1)2] (1), cis‐ and trans‐K[RhCl4(HL2)2] (2a and 2b) and cis‐ and trans‐K[RhCl4(HL3)2] (3a and 3b). Complexes

  我们描述了阴离子[RhCl 6 ] 3-与一系列乙内酰脲配体的反应（HL1，HL2和HL3分别为5-甲基-5-（2-，3-和4-吡啶基）-2,4-咪唑烷二酮） ）。根据光谱，循环伏安，元素分析和质谱分析，该配合物的通式为K [RhCl 2（L1）2 ]（1），顺式和反式-K [RhCl 4（HL2）2 ]（2a和2b）与顺式-和反式-K [的RhCl 4（HL3）2 ]（图3a和图3b）。复合体使用红外，1 H NMR和13 C NMR光谱分析成功地表征了2a，2b，3a和3b。配合物1在二甲亚砜（DMSO）中的溶解导致消除了一个KL1配体并消除了两个作为配体的DMSO分子并将该配合物转化为顺式和反式[RhCl 2 L1（DMSO）2 ]（1a和1b）。重结晶导致1a晶体的分离和分离从最初的混合物。X射线分析结果表明，该配合物结晶为溶剂化的顺式[RhCl 2 L1（DMSO）2 ] DMS
• Palladium(II) complexes with 5-methyl-5-(4-pyridyl)-2,4-imidazolidenedione
  作者：Adriana Bakalova、H. Varbanov、R. Buyukliev、G. Momekov、D. Ivanov

  DOI：10.1007/s10973-007-8937-3

  日期：2009.1

  Two new palladium(II) complexes with 5-methyl-5-(4-pyridyl)-2,4-imidazolidenedione(mpyh) were synthesized: cis-[Pd(mpyh)2Cl2]·H2O and cis-[Pd(mpyh)2Br2]·2H2O. The molecular formulae of the complexes were confirmed by elemental analysis, IR, 1H NMR spectra and DTA study. The ligand is coordinated to the palladium ion with N-atom of the pyridine ring. The spectroscopic data indicate a square planar geometry with two N-pyridine atoms and two halogene anions in cis position. The final product of the thermal decomposition of cis-[Pd(mpyh)2Cl2]·H2O is metallic Pd, whereas for cis-[Pd(mpyh)2Br2]·2H2O the residue consists of metallic Pd and C. The cytotoxic effects of the complexes were examined in vitro on some human tumor cell lines. The cis-[Pd(mpyh)2Cl2]·H2O proved to be more active as compared to the cis-[Pd(mpyh)2Br2]·2H2O.

  合成了两种新的钯(II)与5-甲基-5-(4-吡啶基)-2,4-咪唑基二酮(mpyh)的配合物：cis-[Pd(mpyh)2Cl2]·H2O和cis-[Pd(mpyh) 2Br2]·2 。通过元素分析、IR、1H NMR谱和DTA研究证实了配合物的分子式。该配体通过吡啶环的N原子与钯离子配位。光谱数据表明具有两个N-吡啶原子和两个处于顺式位置的卤素阴离子的方形平面几何形状。 cis-[Pd(mpyh)2Cl2]· 热分解的最终产物是金属Pd，而cis-[Pd(mpyh)2Br2]·2 的残留物由金属Pd和C组成。在一些人类肿瘤细胞系上对复合物进行了体外检查。与 cis-[Pd(mpyh)2Br2]·2 相比，cis-[Pd(mpyh)2Cl2]· 被证明具有更高的活性。
• Therapeutic compounds for treating dyslipidemic conditions
  申请人：Jones Brian A.

  公开号：US20050239769A1

  公开（公告）日：2005-10-27

  The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

  本发明涉及公式I的新型LXR配体及其药学上可接受的盐、酯和互变异构体，其在治疗脂质代谢异常症状，特别是低下的高密度脂蛋白胆固醇水平中有用。